SPARX3
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Brain and Nervous System, Parkinsons Disease
Study Purpose
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. Secondary objectives will test hypotheses related to striatal specific binding ratio (SSBR) at 12 months, MDS-UPDRS Part III score, ambulatory mobility (6-minute walk), daily walking activity (steps), cognition, quality of life, cardiorespiratory fitness, blood-derived biomarkers of inflammation and neurotrophic factors at 12 and 18 months. Exploratory objectives will test hypotheses related to the effects of removing the study support that was provided over 18 months on the sustainability and durability of the exercise effects at 24 months.
Locations
UH Kent Health Center
401 and 408 Devon Place
Kent OH, 44240
UH Suburban Health Center
1611 South Green Road
South Euclid OH, 44121
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
UH Westlake Health Center
960 Clague Road
Westlake OH, 44145
- UH IRB: SITE00001423
- StudyID: 2021-0534
- ClinicalTrials.gov: NCT04284436
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422